Every material Form 8-K Drugs Made In America Acquisition Corp. has filed with the SEC since July 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Drugs Made In America Acquisition Corp. and Power Analytics Global Corp. amended their merger agreement on October 13, 2026. If the APQC Acquisition is not completed by November 1, 2026, or another Reversion Event occurs, the closing valuation automatically falls from $2.85 billion to $1.71 billion on a standalone basis, and the APQC completion condition is removed.
Closing valuation drops from $2.85 billion to $1.71 billion on a standalone basis if a Reversion Event occurs.
Reversion Event triggers include APQC Acquisition not completed by November 1, 2026, termination of the APQC agreement, or an independent director determination that it cannot be completed.
Fairness opinion for the standalone valuation is expected from Joel A. Gallo on or before October 26, 2026, after the prior evaluator's engagement ended October 2, 2026.
On September 8, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered an Amended and Restated Definitive Merger Agreement that replaces the existing agreement in its entirety. The parties set a fixed closing valuation of $2.85 billion for Power Analytics, replacing the prior $1.0 billion target and $300 million floor. Completion depends on conditions including shareholder approval, an acquisition of APQC Inc, and a minimum cash condition, so the deal has not closed.
Amended and Restated Definitive Merger Agreement dated September 8, 2026, replacing the Existing Agreement from April 29, 2026.
Closing valuation of $2.85 billion, replacing the $1.0 billion target valuation and $300 million floor valuation.
Merger Consideration capped at 265,116,279 Domesticated DMAA Common Shares, based on a Reference Price of at least $10.75.
Closing requires shareholder approval, completion of the APQC Acquisition and Available Closing Cash of at least $15 million.
Drugs Made In America Acquisition Corp. filed Amendment No. 3 to its merger agreement with Power Analytics Global Corp, dated July 14, 2026. The amendment requires the former sponsor to forfeit at least 50% of its founder shares, sets a $0.25 to $0.35 per-right tender offer for public rights, and restates minimum cash at a $30 million target and $15 million floor. Shareholders are affected by these changes to dilution, cash at closing, and the affiliated-party structure, which the filing says includes a fairness opinion condition.
Sponsor must forfeit at least 50% of founder shares and surrender 430,000 private placement rights for no consideration.
The company agreed to launch a cash tender, exchange offer, or consent solicitation for public rights at $0.25 to $0.35 per right, before or with the proxy mailing.
Minimum cash target is $30,000,000 with a $15,000,000 floor.
A contingent Amendment No. 4 for a possible three-party combination takes effect only if conditions are met by September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Drugs Made In America Acquisition Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →